# Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral

Source: https://onco.cc/trials/nct01933932/  
OnCo record `nct01933932` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Selumetinib, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC is a phase 3 interventional study registered as NCT01933932 by AstraZeneca, with 510 participants enrolled, started 2013-09-25 and due to reach its primary completion in 2016-06-07. Interventions recorded: Selumetinib, Docetaxel, Placebo, Pegylated G-CSF. Conditions listed: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT01933932
- Phase: 3
- Setting: A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1)
- Sponsor: AstraZeneca
- Enrolled: 510

## Sources

- ClinicalTrials.gov NCT01933932: https://clinicaltrials.gov/study/NCT01933932

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Selumetinib](https://onco.cc/drugs/selumetinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct01933932.json